Serna Bio

Executive Summary

Serna Bio is a London-based biotechnology company founded in 2021 that leverages artificial intelligence and computational data science to discover RNA-targeted small molecule drugs. The company focuses on addressing traditionally 'undruggable' protein targets and novel non-coding RNAs by systematically mapping the human 'druggable RNAome.' Its platform integrates RNA structure prediction, chemical biology, and machine learning to identify small molecule binders that modulate RNA function, opening new therapeutic avenues beyond conventional protein-centric drug discovery. Serna Bio operates in the high-growth field of RNA-targeted therapeutics, which has gained significant traction following the success of RNA-based vaccines and antisense oligonucleotides. As a private, early-stage company, Serna Bio has not yet disclosed specific pipeline candidates or clinical timelines. However, the company's innovative platform positions it to potentially partner with larger pharmaceutical firms seeking to target undruggable pathways. Upcoming catalysts may include the nomination of a lead program, securing Series A funding, or entering into a strategic collaboration. The biotechnology sector remains receptive to AI-driven drug discovery platforms, and Serna Bio's focus on RNA targets differentiates it from many competitors. Its success will depend on experimental validation of its computational predictions and ability to attract capital and partnerships.

Upcoming Catalysts (preview)

• Q4 2026Lead Program Nomination or Preclinical Data Release40% success
• Q3 2026Series A Funding Announcement50% success
• Q1 2027Pharmaceutical Partnership or Collaboration30% success